he U.S. Food and Drug Administration (FDA) is warning
consumers not to take Liqiang 4 Dietary Supplement
Capsules because they contain
glyburide —
a
drug that could have serious, life-threatening consequences
in some people.
Glyburide is a drug used to lower blood sugar, and
is safe and effective when used as labeled in FDA-approved
medications. People who have low blood sugar or those
with diabetes can receive dangerously high amounts
of glyburide by consuming Liqiang 4. Consumers should
immediately stop using these products and seek medical
attention, especially if they are currently being
treated with diabetes drugs or if they have symptoms
of fatigue, excessive hunger, profuse sweating, or
numbness of the extremities. Consumers who have this
product should dispose of it immediately.
The product is sold as part of a shrink-wrapped
two bottle set. One of the 90 capsule bottles is
labeled Liqiang 4 Dietary Supplement Capsules,
the other bottle is promoted as a “bonus
pack” of Liqiang 1. At this time FDA is evaluating
Liquang 1 and other versions of this line of products
to determine their composition and safety. The
product is manufactured by Liqiang Research Institute,
China, and marketed throughout the United States
in herbal stores and through mail order by Bugle
International of Northridge CA.
The FDA learned of the potential problem through
an anonymous consumer complaint and followed up
with testing that revealed the presence of glyburide
in this product.
The product has also been termed "Liqiang
Xiao Ke Ling" (Liqiang Thirst Quenching Efficacious)
in ads in Chinese language publications which also
promote it as useful for the control of diabetes
and being derived from only natural ingredients.
FDA encourages consumers, health care providers,
and caregivers to report any adverse events related
to this product to MedWatch, the FDA's voluntary
reporting program at 1-800-FDA-1088; by FAX at 1-800-FDA-0178;
by mail to MedWatch, Food and Drug Administration,
5600 Fishers Lane, Rockville, MD, 20857-9787; or
online at www.fda.gov/medwatch/report.htm.
####